This laboratory procedure identifies antibodies that attack red blood cells. It exists in two primary forms: direct and indirect. The direct version detects antibodies already bound to the surface of red blood cells, indicating an autoimmune hemolytic anemia, drug-induced hemolysis, or hemolytic disease of the newborn. Conversely, the indirect version identifies free-floating antibodies in the serum capable of binding to red blood cells, often employed in prenatal testing to detect antibodies that could cause hemolytic disease in a fetus.
This assay is crucial for diagnosing and managing conditions where the immune system targets red blood cells, leading to their premature destruction. Accurately identifying these antibodies helps clinicians tailor treatment strategies, such as immunosuppression or blood transfusions. Its development revolutionized the understanding of hemolytic anemias and played a vital role in preventing severe complications, particularly in newborns at risk of erythroblastosis fetalis. The test’s accessibility and reliability have made it an indispensable tool in modern hematology and transfusion medicine.
